Serial 85727303
Dead / Abandoned — Abandoned — no statement of use filed (as of 19 Jun 2017)
What this means for you
This application is over — abandoned 19 Jun 2017. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 85727303
- Mark type
- Design / logo
- Filed
- 12 Sept 2012
- Published for opposition
- 18 Mar 2014
- Abandoned
- 19 Jun 2017
- Attorney of record
- R. Gwen Peterson
Goods and services
- Class 001 — Chemicals: Diagnostic preparations and diagnostic kits comprised of buffers and reagents for clinical, medical laboratory, or research use; antibodies for clinical, medical laboratory, or research use; combinations of antibodies for clinical, medical laboratory, or research use; kits containing buffers and reagents for research use
- Class 005 — Pharmaceuticals: Diagnostic preparations and diagnostic kits comprised of buffers and reagents for medical use; antibodies or antibody sequences for medical use, namely, medical diagnosis; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of infectious disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of cancer; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of autoimmune/inflammatory disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of cardiovascular disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of neurological disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of metabolic disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of respiratory disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of ophthalmic disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of infectious disease, cancer, or autoimmune disease in animals; biologics, namely, vaccines for prophylaxis or treatment of infectious disease or cancer in humans; biologics, namely, vaccines for prophylaxis or treatment of infectious disease or cancer in animals; combinations of antibodies or antibody sequences for medical use, namely, biological preparation for the treatment or prophylaxis of infectious disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of cancer; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of autoimmune/inflammatory disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of cardiovascular disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of neurological disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of metabolic disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of respiratory disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of ophthalmic disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of infectious disease, cancer, or autoimmune disease in animals; combinations of biologics, namely, vaccines for prophylaxis or treatment of infectious disease or cancer in humans; combinations of biologics, namely, vaccines for prophylaxis of treatment of infectious disease or cancer in animals
Owner
- Atreca, Inc., Redwood City, CA, US
- Atreca, Inc., San Carlos, CA, US
Prosecution history
- 19 Jun 2017 — ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
- 19 Jun 2017 — ABANDONMENT - NO USE STATEMENT FILED
- 22 Nov 2016 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Nov 2016 — SOU EXTENSION 5 GRANTED
- 10 Nov 2016 — SOU EXTENSION 5 FILED
- 10 Nov 2016 — SOU TEAS EXTENSION RECEIVED
- 20 Apr 2016 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Apr 2016 — SOU EXTENSION 4 GRANTED
- 05 Apr 2016 — SOU EXTENSION 4 FILED
- 05 Apr 2016 — SOU TEAS EXTENSION RECEIVED
- 03 Dec 2015 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 03 Dec 2015 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 04 Dec 2015 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Dec 2015 — CORRECTED NOA E-MAILED
- 03 Dec 2015 — DIVISIONAL PROCESSING COMPLETE